Literature DB >> 17561591

Mild obstructive sleep apnea syndrome should be treated. Pro.

Lee K Brown1.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17561591      PMCID： PMC2564769     

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN： 1550-9389            Impact factor:   4.062


× No keyword cloud information.
  49 in total

1.  Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up.

Authors:  Yüksel Peker; Jan Hedner; Jeanette Norum; Holger Kraiczi; Jan Carlson
Journal:  Am J Respir Crit Care Med       Date:  2002-07-15       Impact factor: 21.405

2.  Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study.

Authors:  F J Nieto; T B Young; B K Lind; E Shahar; J M Samet; S Redline; R B D'Agostino; A B Newman; M D Lebowitz; T G Pickering
Journal:  JAMA       Date:  2000-04-12       Impact factor: 56.272

3.  Prospective study of the association between sleep-disordered breathing and hypertension.

Authors:  P E Peppard; T Young; M Palta; J Skatrud
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

4.  The association of sleep-disordered breathing and sleep symptoms with quality of life in the Sleep Heart Health Study.

Authors:  C M Baldwin; K A Griffith; F J Nieto; G T O'Connor; J A Walsleben; S Redline
Journal:  Sleep       Date:  2001-02-01       Impact factor: 5.849

5.  Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study.

Authors:  E Shahar; C W Whitney; S Redline; E T Lee; A B Newman; F J Nieto; G T O'Connor; L L Boland; J E Schwartz; J M Samet
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

6.  Association of hypertension and sleep-disordered breathing.

Authors:  E O Bixler; A N Vgontzas; H M Lin; T Ten Have; B E Leiby; A Vela-Bueno; A Kales
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

7.  Effectiveness of continuous positive airway pressure in mild sleep apnea-hypopnea syndrome.

Authors:  C Monasterio; S Vidal; J Duran; M Ferrer; C Carmona; F Barbé; M Mayos; N Gonzalez-Mangado; M Juncadella; A Navarro; R Barreira; F Capote; L R Mayoralas; G Peces-Barba; J Alonso; J M Montserrat
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

8.  Obstructive sleep apnea is independently associated with insulin resistance.

Authors:  Mary S M Ip; Bing Lam; Matthew M T Ng; Wah Kit Lam; Kenneth W T Tsang; Karen S L Lam
Journal:  Am J Respir Crit Care Med       Date:  2002-03-01       Impact factor: 21.405

9.  A randomized controlled trial of continuous positive airway pressure in mild obstructive sleep apnea.

Authors:  Maree Barnes; Danielle Houston; Christopher J Worsnop; Alister M Neill; Ivanka J Mykytyn; Amanda Kay; John Trinder; Nicholas A Saunders; R Douglas McEvoy; Robert J Pierce
Journal:  Am J Respir Crit Care Med       Date:  2002-03-15       Impact factor: 21.405

10.  Randomized crossover trial of two treatments for sleep apnea/hypopnea syndrome: continuous positive airway pressure and mandibular repositioning splint.

Authors:  Heather M Engleman; James P McDonald; David Graham; Glenn E Lello; Ruth N Kingshott; Emma L Coleman; Thomas W Mackay; Neil J Douglas
Journal:  Am J Respir Crit Care Med       Date:  2002-09-15       Impact factor: 21.405
View more
  8 in total

1.  A Conditional Inference Tree Model for Predicting Sleep-Related Breathing Disorders in Patients With Chiari Malformation Type 1: Description and External Validation.

Authors:  Álex Ferré; María A Poca; María Dolore de la Calzada; Dulce Moncho; Aintzane Urbizu; Odile Romero; Gabriel Sampol; Juan Sahuquillo
Journal:  J Clin Sleep Med       Date:  2019-01-15       Impact factor: 4.062

2.  Using the STOPBANG questionnaire and other pre-test probability tools to predict OSA in younger, thinner patients referred to a sleep medicine clinic.

Authors:  Michael J McMahon; Karen L Sheikh; Teotimo F Andrada; Aaron B Holley
Journal:  Sleep Breath       Date:  2017-04-19       Impact factor: 2.816

3.  The utility of home sleep apnea tests in patients with low versus high pre-test probability for moderate to severe OSA.

Authors:  Cathy A Goldstein; Hala Karnib; Katherine Williams; Zunaira Virk; Afifa Shamim-Uzzaman
Journal:  Sleep Breath       Date:  2017-11-22       Impact factor: 2.816

4.  Comparison of American Academy of Sleep Medicine (AASM) versus Center for Medicare and Medicaid Services (CMS) polysomnography (PSG) scoring rules on AHI and eligibility for continuous positive airway pressure (CPAP) treatment.

Authors:  Arkady Korotinsky; Samson Z Assefa; Montserrat Diaz-Abad; Emerson M Wickwire; Steven M Scharf
Journal:  Sleep Breath       Date:  2016-03-11       Impact factor: 2.816

5.  Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea.

Authors:  M J Wolley; E Pimenta; D Calhoun; R D Gordon; D Cowley; M Stowasser
Journal:  J Hum Hypertens       Date:  2017-04-06       Impact factor: 3.012

6.  A pictorial Sleepiness and Sleep Apnoea Scale to recognize individuals with high risk for obstructive sleep apnea syndrome.

Authors:  Cathrin Edelmann; Ramesh Ghiassi; Deborah R Vogt; Martyn R Partridge; Ramin Khatami; Jörg D Leuppi; David Miedinger
Journal:  Nat Sci Sleep       Date:  2017-10-25

7.  Cerebral white matter diffusion properties and free-water with obstructive sleep apnea severity in older adults.

Authors:  Andrée-Ann Baril; Katia Gagnon; Maxime Descoteaux; Christophe Bedetti; Sirin Chami; Erlan Sanchez; Jacques Montplaisir; Louis De Beaumont; Danielle Gilbert; Judes Poirier; Sandra Pelleieux; Ricardo S Osorio; Julie Carrier; Nadia Gosselin
Journal:  Hum Brain Mapp       Date:  2020-03-13       Impact factor: 5.038

8.  Validation of the NoSAS score for screening sleep-disordered breathing: A sleep clinic- based study in Turkey

Authors:  Burcu Oktay Arslan; Zeynep Zeren Uçar; Özgür Batum; Mehmet Nurullah Orman
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 0.973
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.